-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $48

Benzinga·04/21/2026 10:53:57
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $56 to $48.